Amgen company is seeking to defend its osteoporosis franchise with UCB-partnered Evenity (romosozumab), an anti-sclerostin antibody that was approved for postmenopausal osteoporosis in 2019 and ...
The trio includes two bone-building bispecific antibodies – sclerostin and DKK1-targeting AGA2118 and AGA2115 for osteoporosis and brittle bone disease (osteogenesis imperfecta), respectively ...
2162.HK Keymed Biosciences Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback